Erbitux Has Expanded Potential
Erbitux may also be an option as a standalone treatment for head and neck cancer patients who have exhausted all other medical options. Merck KGaA, the German drugmaker and ImClone's European partner, will be presenting midstage clinical data at ASCO investigating Erbitux's use as a monotherapy in these so-called refractory head and neck cancer patients.
ImClone is holding an investor meeting Sunday night, at which analysts are guaranteed to ask company executives about their regulatory strategy vis a vis Erbitux and head and neck cancer. If ImClone does seek a label expansion from the FDA, and approval is awarded, ImClone would receive a $250 million milestone payment from partner Bristol-Myers Squibb.
ImClone shares closed Friday at $72.49, down 47 cents, or 0.64%, while Bristol-Myers finished at $25.47, down 30 cents or 1.19%.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV